Cantor analyst Mara Goldstein, in a note issued before the open, attributed the recent selloff in shares of Radius Health to several factors, including a delay in its abaloparatide-SC NDA filing, lowered expectations for a takeout following Shire's (SHPG) tie-up with Baxalta (BXLT) and an overhang from data pending from a potential competitor. The NDA filing delay "is still a bit confusing," said Goldstein, but she noted that the company would have an obligation to disclose if there were a serious issue causing it. The analyst, who still sees abaloparatide-SC having an opportunity to cannibalize the Forteo market, reiterated a Buy rating and $85 price target on Radius shares.